نتایج جستجو برای: hbf

تعداد نتایج: 869  

Journal: :International Journal of Biological Macromolecules 2021

Hemoglobin-based oxygen carriers have long been pursued to meet clinical needs by using native hemoglobin (Hb) from human or animal blood, recombinantly produced Hb, but the development has impeded safety and toxicity issues. Herewith we report successful production of fetal (HbF) in Nicotiana benthamiana through Agrobacterium tumefaciens-mediated transient expression. HbF is a heterotetrameric...

Journal: :Clinical chemistry 1998
J R Conejo T Parra M Cantero A Jiménez V Granizo G de Arriba F Carballo

higher MetHb values in the presence of HbF. For MetHb concentrations of 15% or less, i.e., values most likely to be encountered clinically with NO therapy, the Corning 270, in agreement with the study carried out previously (5), was unaffected by the presence of HbF in the umbilical cord sample (P 5 0.7380). By contrast, the Chiron 800 showed a constant error to significantly higher MetHb (P 5 ...

Journal: :Blood 2012
Harold T Bae Clinton T Baldwin Paola Sebastiani Marilyn J Telen Allison Ashley-Koch Melanie Garrett W Craig Hooper Christopher J Bean Michael R Debaun Dan E Arking Pallav Bhatnagar James F Casella Jeffrey Renn Keefer Emily Barron-Casella Victor Gordeuk Gregory J Kato Caterina Minniti James Taylor Andrew Campbell Lori Luchtman-Jones Carolyn Hoppe Mark T Gladwin Yingze Zhang Martin H Steinberg

Fetal hemoglobin (HbF) protects against many but not all of the hematologic and clinical complications of sickle cell anemia.1,2 This protection is dependent on the ability of HbF to hinder deoxyHbS polymerization. HbF level is variable and highly heritable. Previous genetic association studies found single nucleotide polymorphisms (SNPs) in regions of BCL11A (chromosome 2p), in the HBS1L-MYB i...

2016
Gift Dineo Pule Shaheen Mowla Nicolas Novitzky Ambroise Wonkam

BACKGROUND The major therapeutic benefit of hydroxyurea, the only FDA-approved pharmacologic treatment for sickle cell disease (SCD), is directly related to fetal hemoglobin (HbF) production that leads to significant reduction of morbidity and mortality. However, potential adverse effects such as infertility, susceptibility to infections, or teratogenic effect have been subject of concerns. The...

Journal: :TheScientificWorldJournal 2002
Martin H Steinberg

High fetal hemoglobin (HbF) levels inhibit the polymerization of sickle hemoglobin (HbS) and reduce the complications of sickle cell disease. Pharmacologic agents that can reverse the switch from gamma- to beta-chain synthesis--gama-globin chains characterize HbF, and sickle beta-globin chains are present in HbS--or selectively increase the proportion of adult erythroid precursors that maintain...

ژورنال: :فصلنامه پژوهشی خون 0
فهیمه خوش نقش f. khoshnaghsh مرکز تحقیقات انتقال خون - مؤسسه عالی آموزشی و پژوهشی طب انتقال خون - مریم خیراندیش m. kheirandish مرکز تحقیقات انتقال خون - مؤسسه عالی آموزشی و پژوهشی طب انتقال خونسازمان اصلی تایید شده: سازمان انتقال خون ایران (blood transfusion research center) محمدرضا دیهیم m.r. deyhim مرکز تحقیقات انتقال خون - مؤسسه عالی آموزشی و پژوهشی طب انتقال خونسازمان اصلی تایید شده: سازمان انتقال خون ایران (blood transfusion research center)

چکید ه   سابقه و هدف   فلوسایتومتری روشی مناسب، سریع، دقیق و قابل اعتماد جهت ارزیابی میزان خونریزی های جنینی ـ مادری ( fmh ) می باشد. هدف از این مطالعه، بررسی میزان fmh با استفاده از شاخص آنتی ژنیک rhd وهموگلوبین جنینی( hbf ) به روش فلوسایتومتری است.   مواد و روش ها   در یک مطالعه تجربی، 34 نمونه خون بند ناف نوزاد rh مثبت با خون فرد بالغ rhd منفی به صورت رقیق سازی سریالی در 6 رقت(125/0، 25/0، 5...

Journal: :American journal of medical genetics 1987
D J Odenheimer S A Sarnaik C F Whitten D L Rucknagel C F Sing

A study was conducted in a sample of 140 children with sickle cell anemia to evaluate the relationship between hematological variables (%HbF, %HbA2, %Hb, and mean cell volume) and disease severity. A patient's severity status was determined by whether he/she was hospitalized, had a transfusion, and/or had a pain crisis at 2 evaluation periods; the first was based on a patient's history taken at...

2016

Background: Sickle Cell Anemia (SCA) is the most common monogenic disorder that is inherited as an autosomal recessive pattern. Fetal hemoglobin (HbF) plays a major role in ameliorating clinical severity of the SCA where higher expression of HbF is associated with a reduction in the painful episode and thus reduces the number of hospitalization. The current work aimed to investigate the effect ...

Journal: :Blood 2003
Yogen Saunthararajah Cheryl A Hillery Don Lavelle Robert Molokie Louise Dorn Linda Bressler Stefana Gavazova Yi-Hsiang Chen Ronald Hoffman Joseph DeSimone

Fetal hemoglobin (HbF) decreases polymerization of sickle hemoglobin (HbS) and improves outcomes in sickle cell disease (SSD). Therefore, a therapeutic goal in SSD is pharmacologic reactivation of HbF. Silencing of the gamma-globin (HbF) gene is associated with DNA methylation. The cytosine analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting DNA methyltransferase. We exa...

2018
Olivier Humbert Christopher W. Peterson Zachary K. Norgaard Stefan Radtke Hans-Peter Kiem

Reactivation of fetal hemoglobin (HbF) is a promising approach for the treatment of β-hemoglobinopathies and the targeting of genes involved in HbF regulation is under intensive investigation. Here, we established a nonhuman primate (NHP) transplantation model to evaluate hematopoietic stem cell (HSC)-based gene editing strategies aimed at reactivating HbF. We first characterized the transient ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید